Adagloxad simolenin

Drug Profile

Adagloxad simolenin

Alternative Names: Globo H-KLH; Globo-H vaccine; OBI 822; OBI-822/OBI-821; OPT-822/821; OPT-822/OPT-821

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer OBI Pharma
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 04 Jun 2016 Efficacy data from a phase II/III trial in Brest cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 22 Feb 2016 OBI Pharma plans a phase III trial for Breast cancer
  • 22 Jun 2015 OBI 822 is still in phase II/III development for Breast cancer in USA, China, India, Hong Kong, Malaysia and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top